Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Teriparatide better than risedronate for preventing fractures despite psychotropic, PPI exposure

20 Nov 2019

Exposure to psychotropic drugs and proton pump inhibitors (PPIs) contributes to an increase risk of clinical and nonvertebral fractures in postmenopausal women with severe osteoporosis, according to a study. Furthermore, teriparatide confers superior benefits for reducing the risk of fractures compared with risedronate, irrespective of such an exposure.

Researchers conducted a posthoc analysis of the fracture-endpoint study VERO, which evaluated the effect of subcutaneous daily teriparatide 20 μg vs oral weekly risedronate 35 mg in women with established osteoporosis. They assessed the risk of fractures in relation to exposure to psychotropic drugs (hypnotics, benzodiazepines and antidepressants) and proton pump inhibitors (PPIs), including potential interactions with the assigned clinical trial drugs.

Of the women, 406 (29.9 percent) were exposed to PPIs, 347 (25.5 percent) to benzodiazepines/hypnotics, and 176 (12.9 percent) to selective serotonin- and norepinephrine-reuptake inhibitors (SSRIs/SNRIs) during the study. The risk-reduction advantage observed with teriparatide vs risedronate for all fracture endpoints did not significantly differ within the categories of psychotropic drugs and PPIs.

Multivariable analysis showed that PPI use vs nonuse was associated with a heightened risk of pooled new and worsened vertebral fractures (risk ratio, 1.57; p=0.032), regardless of the study treatment. On the other hand, benzodiazepine/hypnotic drug use was associated with increased risks of clinical fractures (hazard ratio [HR], 1.71; p=0.026) and nonvertebral fragility fractures (HR, 1.89; p=0.017), regardless of the study treatment.

Likewise, SSRI/SNRI use contributed to an increased risk of clinical fractures (HR, 1.93; p=0.018) and nonvertebral fragility fractures (HR, 2.16; p=0.011), regardless of the study treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.